Dr. Lal PathLabs’ board approved a bonus issue of 1:1, a dividend of ₹7 per share, and an employee stock option plan. The company will increase authorized share capital to ₹200 crore and introduced a new employee restricted stock unit plan for 2025. They also approved the voluntary liquidation of Suburban Diagnostics, consolidating business within the parent company. The record date for the dividend is November 7, 2025.
Financial Highlights and Dividend
Dr. Lal PathLabs announced a ₹7 per share dividend to be paid to shareholders. The record date to be eligible for the dividend is November 7, 2025. The dividend reflects the company’s continued profitability and its commitment to delivering shareholder value.
Bonus Issue Details
The Board approved the issuance of bonus equity shares in a ratio of 1:1, meaning one bonus share for each existing share held. The bonus issue is subject to shareholder and regulatory approvals. Further details regarding the record date for the bonus issue will be announced in due course.
Capital Restructuring & Employee Benefits
Dr. Lal PathLabs is increasing its authorized share capital from approximately ₹107.96 million to ₹200 million. This will be achieved by amending the Memorandum of Association (MOA) and issuing new equity shares. A new employee restricted stock unit plan, “RSU 2025”, has been initiated and will provide stock options to employees.
Subsidiary Restructuring
The company is moving ahead with the voluntary liquidation of Suburban Diagnostics (India) Private Limited and the transfer of its business operations to the parent entity, Dr. Lal PathLabs. This restructuring is anticipated to streamline operations and improve efficiency.
Q2 Financial Performance
For Q2 (Jul-Sept) 2025, Dr. Lal PathLabs reported revenue from operations of ₹7,306 million, compared to ₹6,602 million in Q2 of the previous fiscal year. Net profit for the period was ₹1,522 million. The results include contributions from its various subsidiaries, including Paliwal Diagnostics and Dr. Lal PathLabs Nepal, among others.
Source: BSE
